Phathom Pharmaceuticals (PHAT) announced that the Food and Drug Administration has approved the company’s citizen petition filed on December 11, 2024 and communicated the agency’s intention to correct the Orange Book to recognize the proper 10 years of new chemical entity exclusivity for Voquenza tablets, extending through May 3, 2032.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Phathom Pharmaceuticals price target lowered to $12 from $18 at Guggenheim
- Phathom Pharmaceuticals price target lowered to $20 from $28 at H.C. Wainwright
- Phathom Pharmaceuticals Reports Q1 2025 Financial Results